**Core tip:** Procyanidins are widely recognized for their excellent antioxidant properties and fewer side effects compared to other drugs. In the past, the mechanism of procyanidin to improve insulin resistance mainly focused on the antioxidant effect. The effect of procyanidin on non-alcoholic fatty liver disease is not clear. We found that procyanidin can reduce fatty liver by remodeling intestinal flora, decreasing endotoxemia, and down-regulating fatty acid synthesis genes. Our results open a new chapter in the mechanism of action of plant compounds and suggest a safer method for the treatment of non-alcoholic fatty liver disease.

INTRODUCTION
============

Advances in industrialization have changed people\'s lifestyles and eating habits. The incidence of obesity has rapidly increased, along with an increase in obesity-related metabolic syndrome, such as non-alcoholic fatty liver disease (NAFLD). NAFLD refers to the pathological state in which lipid, carbohydrates, and other substances are metabolically disordered. It is complex and is a risk factor for cardiovascular diseases and diabetes\[[@B1]\]. NAFLD is characterized by insulin resistance (IR) caused by a combination of genetic and environmental factors. Common manifestations include endotoxemia, low-grade inflammation, and tissue damage\[[@B2]-[@B4]\]. The intestinal barrier serves as the first site of interaction between the diet and the host immune system. This interaction can affect the composition of the gut microbiota, which affects intestinal immune homeostasis and intestinal permeability\[[@B5],[@B6]\]. Thus, the gut and its microflora are potential sources of pro-inflammatory molecules that can affect systemic metabolism and may be involved in early events related to IR and NAFLD.

Evidence indicates that changes in intestinal mucosal permeability caused by a dysfunctional gut microbiota and metabolites produced by bacteria initiate the development of obesity-related metabolic diseases\[[@B7],[@B8]\]. Lipopolysaccharides (LPS) derived from the gut microbiota are effective inflammation-inducing agents and play important roles in the occurrence and development of inflammation and related NAFLD\[[@B7],[@B9]\]. A high-fat diet is associated with elevated systemic circulating levels of LPS (endotoxemia). Moreover, it causes an imbalance in the gut microbiota, especially by changing the proportion of *Firmicutes* and *Bacteroides*, and this is thought to play a key role in the pathogenesis of NAFLD\[[@B10]\]. The treatment of mice with broad-spectrum antibiotics can reshape the gut microbiota and improve insulin sensitivity\[[@B11]\]. Therefore, the gut microbiota is a potential source of pro-inflammatory molecules that can affect systemic metabolism and appear before the development of obesity and metabolic syndrome.

Proanthocyanidins are polyphenolic plant compounds that are naturally present in the diet\[[@B12]\]. Owing to their anti-oxidative, anti-inflammatory, and anti-atherogenic properties, they have been studied extensively. Procyanidin B2 (PB2), an oligomeric anthocyanin precursor, is widely distributed in grapes, cranberries, and other berries. PB2 has been reported to improve dyslipidemia, hyperglycemia, and oxidative stress in individuals with metabolic syndrome through its anti-oxidative properties\[[@B13]\]. However, PB2 is a natural plant compound, and its bioavailability in humans is low\[[@B12],[@B14]\]. The low levels of PB2 in the body make their superior effects difficult to explain. The mechanism underlying the beneficial effects of PB2 remains largely unknown. Recent growing evidence shows that procyanidin has strong antimicrobial effects against bacteria, fungi, and viruses and can rejuvenate the gut microbiota for health benefits\[[@B15]\]. A diet supplemented with proanthocyanidins can regulate the microbial composition in pig intestines and reduce the infection rate of swine mites. Given the close association between metabolic syndrome, the gut microbiota, and PB2, the purpose of this study was to determine the effects of PB2 on the metabolism of a high-fat-fed New Zealand white rabbits and to determine whether these effects are related to modulation of the gut microbiota.

MATIERIALS AND METHODS
======================

Animal model, diet, and experimental procedures
-----------------------------------------------

Thirty New Zealand white rabbits (male, 2-mo-old, mean weight 2.0 ± 0.2 kg) were purchased from Shanghai Silaike Experimental Animal Co. LTD (Shanghai, China). Rabbits were housed in individual cages at a controlled temperature (22 ± 2 °C), with a 12-h light/dark period. Animals were fed either a chow (standard diet: 20% corn, 30% grass powder, 20% cardamom, 25% wheat bran, 5% multivitamins, FBSH Biotechnology Inc.) or a high-fat-cholesterol diet (HCD) (10% lard, 0.5% cholesterol, 5% sucrose, 1% maltodextrin, FBSH Biotechnology Inc.). After 2 wk of a high-fat, cholesterol diet, some rabbits were excluded because of very high (\> 2 mmol/L) or low (\< 0.5 mmol/L) cholesterol levels\[[@B16]\]. Group PB2 (fed a HCD, *n* = 8) received daily doses (150 mg/kg, dissolved in normal saline) of PB2 by gavage\[[@B17]\], whereas the other two groups \[groups CHOW and HCD, fed a chow or HCD, *n* = 8\] received the vehicle (normal saline) by gavage. Body weight gain and other parameters were evaluated once a week. Feces were collected at the end of 12 wk for 16S rRNA sequencing. After 12 wk, the rabbits were euthanized by barbiturate overdose (intravenous injection, 150 mg/kg pentobarbital sodium) for blood and tissue collection. The livers were weighed and the liver index (the ratio of liver to body weight) was calculated. The protocol was approved by the Animal Research Committee of the Second Xiangya Hospital, Central South University, Hunan, China (permit number: 20170722). The chemicals used in this study were of analytical grade. PB2 (≥ 95% purity) was purchased from Yuanye Biological Technology Co. Ltd. (Shanghai, China).

Measurement of serum biochemical markers
----------------------------------------

Blood samples were collected from the middle artery of the ear after overnight fasting at the end of 10 wk. The concentrations of serum total cholesterols (CH), triglycerides (TG), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), serum alanine transaminase (ALT), aspartic acid transferase (AST), and glucose (GLU) were detected by enzymatic methods (BioMerieux, Lyon, France). At the end of the experiment, the intravenous glucose tolerance test (IVGTT) was performed. After fasting overnight, a bolus of glucose (0.6 g/kg body weight) was injected into the ear vein, and blood samples were collected from the middle artery at 0, 5, 10, 30, 60, and 120 min. The serum insulin concentrations were analyzed according to the protocols of the Rabbit Insulin ELISA Kit (Crystal Chem Co., Elk Grove Village, IL, United States). The serum LPS concentration was determined using a kit based on a Limulus amebocyte extract (LAL Kit; Lonza, Basel, Switzerland).

Histological analysis
---------------------

After the rabbits were sacrificed, a morphological analysis of liver tissues was performed on hematoxylin and eosin-stained sections. Liver tissue samples were fixed with 10% neutral buffered formalin for 24 h, dehydrated with an ethanol solution, and embedded in paraffin. Tissue sections of 5 μm-6 μm in thickness were excised, deparaffinized, rehydrated, and stained with hematoxylin and eosin.

Quantitative real-time polymerase chain reaction (PCR)
------------------------------------------------------

Liver was homogenized and total RNA was isolated using the RNeasy kit (Qiagen, Hilden, Germany). A reverse transcription reaction was performed by Taqman Reverse Transcription reagent kit (Takara, Kusatsu, Japan) according to the manufacturer\'s instructions. The real-time PCR reaction was carried out on Roche real-time PCR system with cDNA sample containing SYBR Green PCR master mix (Takara) and primers. Primer sequences can be made available upon request. Relative expression of mRNA was calculated by the comparative cycle threshold method.

Bacterial DNA extraction and PCR amplification
----------------------------------------------

Microbial genomic DNA was extracted from fecal samples using the QIAamp DNA Stool Mini Kit (Qiagen). The V4 hypervariable region of 16S rRNA was amplified by PCR using specific barcoded primers (515F: 5′-GTGCCAGCMGCCGCGGTAA-3', 806R: 5'-GGACTACHVGGGTWTCTA AT-3'). All PCR procedures were performed using Phusion High-Fidelity PCR Master Mix (New England Biolabs, Ipswich, MA, United States). A mixture of PCR products was purified using the Qiagen Gel Extraction Kit. The PCR products were used to generate a sequencing library using the TruSeq DNA PCRFREE Sample Preparation Kit (Illumina, San Diego, CA, United States). Finally, the library was sequenced using the Illumina HiSeq 2500 platform.

Bioinformatics analysis of sequencing data
------------------------------------------

The 16S raw data for all samples were processed and analyzed using the QIIME pipeline (1.9.1). Operational taxonomic units (OTUs) were clustered with a 97% similarity. A representative sequence for each OTU was selected and was classified using the Greengene database gg_13_8. Based on the analysis of OTUs, the species with the highest abundance at each taxonomic level for each sample was selected to generate the relative abundances of species. An unweighted UniFrac principal coordinate analysis (PCoA) was used to analyze the similarity in the composition of fecal flora in rabbits.

Statistical analysis
--------------------

The measurement data obtained in the study were expressed as means ± standard deviation, and the differences were analyzed by one-way analysis of variance. Statistical analyses were performed using SPSS 22.0 (Armonk, NY, United States). Differences were statistically significant when *P* \< 0.05.

RESULTS
=======

Effects of PB2 on body weight gain and the serum lipid profile
--------------------------------------------------------------

To investigate the metabolic effects of PB2 on HCD, body weight and serum biomarkers were detected. The treatment of HCD-fed rabbits with PB2 prevented an increase in body weight, and this effect was observed after just 3 wk (Figure [1A](#F1){ref-type="fig"} and B). By the end of 12-wk period, the Chow group gained the least body weight. The body weight of the PB2 group was slightly higher than that of the Chow group but was much lower than that of the HCD group (*P* \< 0.05). The HCD and PB2 groups required a period of adaptation to the HCD and exhibited reduced food intake. Throughout the experiment, the PB2 group consumed the least amount of food. There was no significant difference in food intake between the three groups of rabbits after the acclimation period (Figure [1C](#F1){ref-type="fig"}). At the end of the experiment, the liver index of the PB2 group was significantly lower than that of the HCD group (Figure [1D](#F1){ref-type="fig"}).

![Effects of procyanidin B2 on body composition. A: Weight gain curves; B: Total weight gain; C: Food intake curves; D: Liver index. The data are expressed as means ± SD. ^a^*P* \< 0.05 *vs* CHOW group; ^b^*P* \< 0.05 *vs* high-fat-cholesterol diet group. HCD: High-fat-cholesterol diet; PB2: Procyanidin B2; SD: Standard deviation.](WJG-25-955-g001){#F1}

Several serum biochemical parameters, including TG, CH, LDL-C, HDL-C, GLU, and insulin, were determined. The values of TG, CH, and LDL-C were lowest in the Chow group. PB2 administration reduced serum TG, CH, and LDL-C levels compared with levels in the HCD group, ameliorating HCD-induced hypertriglyceridemia and hypercholesterolemia in these rabbits (*P* \< 0.05) (Figure [2A](#F2){ref-type="fig"}-C). PB2 also significantly improved HDL-C levels compared with those in the HCD group (*P* \< 0.05) (Figure [2D](#F2){ref-type="fig"}). Although PB2-treated HCD-fed rabbits did not show improved fasting glucose compared to that of the HCD group, these animals displayed lower concentrations of fasting insulin than those in untreated HCD-fed animals (*P* \< 0.05) (Figure [2E](#F2){ref-type="fig"} and F). The IVGTT was performed, and changes in serum glucose are presented in Figure [2G](#F2){ref-type="fig"}. The incremental area under the curve (AUC) for glucose in the PB2 group was lower than that in the HCD group (Figure [2H](#F2){ref-type="fig"}), but the difference was not statistically significant. Twelve weeks of HCD feeding produced a significant increase in circulating LPS, which was partially prevented by PB2 administration (*P* \< 0.05) (Figure [2I](#F2){ref-type="fig"}). Thus, PB2 alleviated the endotoxemia induced by HCD.

![Effects of procyanidin B2 on serum lipid profile, insulin resistance, and endotoxemia. Serum triglycerides (A), total cholesterol (B), low-density lipoprotein cholesterol (C), high-density lipoprotein cholesterol (D) and fasting glucose (E), fasting insulin (F) and the intravenous glucose tolerance test (G), units of area under the curve (H) and lipopolysaccharides (I). The data are expressed as means ± SD. ^a^*P* \< 0.05 *vs* CHOW group; ^b^*P* \< 0.05 *vs* high-fat-cholesterol diet group. HCD: High-fat-cholesterol diet; PB2: Procyanidin B2; LDL-C: Low-density lipoprotein cholesterol; HDL-C: High-density lipoprotein cholesterol; IVGTT: Intravenous glucose tolerance test; AUC: Area under the curve; LPS: Lipopolysaccharides; SD: Standard deviation.](WJG-25-955-g002){#F2}

Effects of PB2 on diet-induced hepatic steatosis in rabbits
-----------------------------------------------------------

Since PB2 could inhibit hypertriglyceridemia and hypercholesterolemia in rabbits, we next examined the effects of PB2 on HCD-induced hepatic steatosis. We performed a histological analysis of the liver by staining with hematoxylin and eosin to investigate the effect of PB2 on hepatic triglyceride accumulation. The HCD group showed obvious triglyceride accumulation in the liver. The administration of PB2 resulted in significantly less triglyceride accumulation compared with that in the HCD group. The Chow group had undetectable triglycerides in the liver by hematoxylin and eosin staining (Figure [3A](#F3){ref-type="fig"}). At the end of the experiment, the liver weight in the HCD group was significantly higher than that of the Chow group (*P* \< 0.05). PB2 treatment significantly reduced liver weight compared to the HCD group (*P* \< 0.05) (Figure [3B](#F3){ref-type="fig"}). There was no significant difference in liver enzymes among the three groups (Figure [3C](#F3){ref-type="fig"} and D). Moreover, compared to the HCD group, PB2 treatment partially prevented the upregulation of the steroid response element binding protein 1c (SREBP‐1c) and the downregulation of carnitine palmitoyltransferase (*P* \< 0.05) (Figure [3E](#F3){ref-type="fig"}-G). The expression of fatty acid synthase (FASN) was also decreased compared with the HCD group, but the difference was not significant.

![Effects of procyanidin B2 on hepatic steatosis. A: Hematoxylin and eosin staining of liver in CHOW group, HCD group and procyanidin B2 group; B: Liver weight; C: Alanine transaminase; D: Aspartate transaminase; E: Relative expression levels of steroid response element binding protein 1c; F: Relative expression levels of fatty acid synthase; G: Relative expression levels of carnitine palmitoyltransferase. The data are expressed as means ± SD. ^a^*P* \< 0.05 *vs* CHOW group; ^b^*P* \< 0.05 *vs* HCD group. HCD: High-fat-cholesterol diet; PB2: Procyanidin B2; ALT: Alanine transaminase; AST: Aspartate transaminase; SREBP-1c: Steroid response element binding protein 1c; FASN: Fatty acid synthase; CPT: Carnitine palmitoyltransferase; SD: Standard deviation.](WJG-25-955-g003){#F3}

Effects of procyanidin on the gut microbiota
--------------------------------------------

The overall composition of the gut microbiota in each group was investigated. For each sample, the V4 hypervariable region of the bacterial 16S rRNA gene sequence was amplified by PCR. After filtering out sequences with a low mass and short length, 1800802 high-quality reads were obtained (average, 78295 sequences per sample). We identified 3612 OTUs based on the conventional criterion of a 97% sequence identity (equal to the species level). The coverage index (sequencing depth index) for all samples ranged from 0.984 to 0.996.

Unweighted UniFrac PCoA differentiated microbial communities based on diet and treatment were generated. As shown in Figure [4A](#F4){ref-type="fig"}, PCoA revealed that the HCD diet promoted major alterations in the gut microbiota. Distinct clusters were observed for PB2-treated rabbits, Chow-fed rabbits, and HCD-fed rabbits. These results demonstrated that PB2 administration has a significant effect on gut microbial composition in HCD-fed rabbits. A total of 10 phyla were detected, and *Firmicutes, Bacteroidetes, Proteobacteria, and Tenericutes* were the most abundant phyla in these samples (Figure [4B](#F4){ref-type="fig"}). At the phylum level, the proportion of *Bacteroidetes* was significantly reduced in the HCD-fed rabbits (*P* \< 0.05), whereas the relative abundance of *Proteobacteria* was significantly increased compared to that of the Chow-fed rabbits (*P* \< 0.05). Similar trends for *Bacteroidetes* and *Proteobacteria* were observed in Chow-fed animals and PB2-treated animals. PB2 administration led to a low ratio of *Firmicutes* to *Bacteroidetes* (*P* \< 0.05).

![Effects of procyanidin B2 on gut microbiota. A: Principal coordinate analysis of the gut microbiota based on unweighted UniFrac distances between groups; B: Relative abundance of gut microbiota in phylum; C: Venn diagrams described the number of operational taxonomic units that are distinct and shared across the groups; D: Heatmap: Community hierarchical clustering analysis of major taxonomic groups at genus level, the red represents high relative abundance and the blue represent low relative abundance; E: Relative abundance of gut microbiota in genus. HCD: High-fat-cholesterol diet; PB2: Procyanidin B2; PCoA: Principal coordinate analysis; OTUs: Operational taxonomic units.](WJG-25-955-g004){#F4}

At the genus level, there were significant alterations in *Allobaculum, Ruminococcus, Bacteroidetes*, and *Akkermansia* (Figure [4D](#F4){ref-type="fig"} and E). Compared with the HCD group, the relative abundance of *Allobaculum* was significantly reduced in the PB2 group and the relative abundances of *Ruminococcus* and *Bacteroidetes* were significantly increased. Of note, PB2 treatment was associated with a striking 3-fold increase in the relative abundance of *Akkermansia* compared with that of the HCD group.

Different numbers of OTUs were detected in each group, *i.e*. 2941 in the Chow group, 2940 in the HCD group, and 2712 in the PB2 group (Figure [4C](#F4){ref-type="fig"}). Among all OTUs, 2166 were shared by all groups. Additionally, each group had unique OTUs, including 174 in the Chow group, 210 in the HCD group, and 274 in the PB2 group.

DISCUSSION
==========

In the current study, we used an HCD-induced model to investigate the effects of PB2 on several components of metabolic syndrome. Our results suggested that PB2 prevents HCD-induced weight gain and the development of NAFLD and improves insulin sensitivity. PB2 also prevented the upregulation of several lipogenic genes, including SREBP‐1c and FASN. Moreover, PB2 administration led to a dramatic alteration in the gut microbiota by increasing the proportion of *Bacteroidetes* at the phylum level and *Akkermansia* at the genus level.

Extensive evidence indicates that high polyphenol-rich fruit consumption is negatively correlated with several features of metabolic syndrome\[[@B18]-[@B20]\]. Although the positive health effects of fruit may be attributed to vitamins, minerals, and dietary fiber, a growing number of studies support the role of polyphenols in protection against obesity-related diseases\[[@B21]\]. Accordingly, we explored the impacts of PB2, a major component of berries, on several features of NAFLD\[[@B22],[@B23]\]. Our results showed that PB2 reduces weight gain as well as the liver index, and this effect on weight was observed before significant change of food intake was detected. IVGTT revealed an improvement in IR by fasting and postprandial glucose in the PB2 group compared with the HCD group. PB2 treatment had an obvious lipid-lowing effect; it significantly reduced the serum levels of TG, TC, and LDL-C compared to the HCD group at the end of the experiment. Additionally, PB2 prevented the development of NAFLD to some extent by reducing liver TG deposition and weakened inflammation induced by the HCD.

SREBP-1c is a major regulator of fatty acids (FA) synthesis, which may be involved in IR and NAFLD development, with the goal of reducing lipogenesis and TG levels. Overexpressing SREBP1c increased FA synthase, leading to a higher level of liver FA and TG; whereas SREBP-1c knockout mice showed decreased FASN expression, liver FA, and serum TG levels\[[@B24]\]. Our results showed that PB2 significantly prevented the upregulation of SREBP-1c compared to the HCD group. The inhibition of SREBP1 upregulation may be included in the mechanisms of PB2 to alleviate the steatosis in hepatic cells.

A high ratio of *Firmicutes* to *Bacteroidetes* is often thought to be a key characteristic of obesity and NAFLD\[[@B25]\]. Ciubotaru et al\[[@B26]\] have reported that a high proportion of *Bacteroidetes* is associated with better glycemic control in humans. Rabot et al\[[@B27]\] found that the transplantation of a Bacteroides-rich microbiota improves glucose intolerance caused by an HCD in mice. Fernando reported that a lower *Firmicutes* to *Bacteroidetes* ratio is associated with improved glucose and insulin tolerance after cranberry extract administration\[[@B28]\]. Similar to previous results, we observed the partial recovery of IR and reshaping of gut microbiota induced by HCD after PB2 treatment. Future studies are warranted to determine whether the ratio of *Firmicutes* to *Bacteroidetes* influences host glucose homeostasis prior to fat mass accumulation.

The gut microbiota has a casual role in the pathogenesis of NAFLD\[[@B5]\]. Previous reports have suggested that polyphenolic plant compounds have poor absorption and are mainly absorbed in the intestines\[[@B13]\]. This prompted us to assess the impact of PB2 on gut microbiota. We demonstrated that an HCD leads to a dramatic shift in the gut microbiota of rabbits by decreasing the proportion of *Bacteroidetes* and increasing the ratio of *Firmicutes* to *Bacteroidetes*, whereas PB2 treatment changed this trend. This diet-induced remodeling of gut microbial communities in HCD-fed rabbits is a typical feature of obesity-driven dysbiosis and is in agreement with previous results\[[@B10]\].

According to our results, it is possible that PB2 influences metabolic phenotypes by regulating the relative abundance of *Akkermansia*. This is consistent with several previous studies that plant compounds can have a significant impact on the proportion of *Akkermansia* in the gut microbiota of an animal model\[[@B25]-[@B30]\]. The administration of cranberry extract to high fat-fed mice is associated with the relative proportion of *Akkermansia*, whereas a study revealed that treatment of HCD-fed mice with green tea polyphenols can modulate the gut microbial ecosystem (*in vitro*) by increasing the proportion of *Akkermansia*. In addition, the metabolic benefit of resveratrol is also associated with an increased intestinal abundance of the bacteria. Similarly, our results suggest that treatment with PB2, a plant compound, leads to an increase in the *Akkermansia* population and might be sufficient to prevent the negative metabolic phenotype caused by an HCD.

Hepatic steatosis involves the deposition of TG, which together with oxidative stress, constitutes the basis for the pathophysiology of NAFLD. In obese patients, LPS from the intestinal microbiota enters the liver through the portal vein and affects physiological metabolic processes in the host\[[@B31]\]. In our experiments, LPS levels in the HCD-fed rabbits were higher than those in the Chow group, and the change was partially reversed by treatment with PB2. Interestingly, the use of *Akkermansia* as a probiotic could reduce serum LPS levels in mice fed an HCD. This may be explained by the ability of *Akkermansia* to retain the thickness of the intestinal mucus layer, thus reducing intestinal permeability and LPS leakage. Therefore, the ability of PB2 to reduce serum LPS levels in our experiments could explain the reduction in liver TG accumulation and the protection against hepatic oxidative stress and inflammation in HCD-fed rabbits.

While our study provides evidence for the beneficial effects of PB2 for the treatment of NAFLD, some limitations must be acknowledged. Further studies should evaluate whether its effects on metabolic phenotype are mediated by the metabolic products of the gut microbiota, such as trimethylamine-*N*-oxide or bile acids.

In summary, we found that PB2 treatment protects against HCD-induced obesity, IR, and liver steatosis in rabbits. These effects were associated with the alleviation of intestinal inflammation and metabolic endotoxemia. These results led us to propose that PB2 may prevent obesity and NAFLD by a prebiotic effect on the gut microbiota.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

The mechanism of procyanidin to improve metabolic syndrome mainly focuses on its antioxidant effect. The latest studies show that procyanidin have commendable antibacterial properties. The evaluation of remodeling gut microbiota in non-alcoholic fatty liver disease (NAFLD) by procyanidin may provide a new therapeutic trend.

Research motivation
-------------------

Procyanidin has been reported to improve dyslipidemia, hyperglycemia, and oxidative stress through its anti-oxidative properties. However, procyanidin is a natural plant compound, and its bioavailability in humans is low. The low levels of procyanidin B2 (PB2) in the body make their superior effects difficult to explain. The mechanism underlying the beneficial effects of procyanidin remains largely unknown.

Research objectives
-------------------

To validate the effect of procyanidin on NAFLD and to clarify the possible mechanism of action.

Research methods
----------------

New Zealand white rabbits were fed chow or high-fat-cholesterol diet (HCD) for 12 wk. The body weight was investigated every week. The serum samples were analyzed after a 12-wk time. Hematoxylin and eosin staining of liver samples were performed, and fatty acid synthesis genes of liver were evaluated. The gut microbiota was sequenced by 16S rRNA analysis.

Research results
----------------

Our results show that procyanidin is associated with alleviated hepatic steatosis, decrease serum lipid, suppressed gut inflammation, and remolded gut microbiota.

Research conclusions
--------------------

Procyanidin treatment protects against HCD-induced obesity, insulin resistance, and liver steatosis in rabbits. These effects were associated with the alleviation of intestinal inflammation and endotoxemia.

Research perspectives
---------------------

Plant compounds, such as procyanidin, should be further explored for their potential therapeutic activity in NAFLD.
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